Read Wysa’s 2023 Employee Mental Health Report, as launched at World Economic Forum. Learn more
Latest at Wysa
Wysa Secures $20m to Address Global Mental Health Demand With AI Digital Therapeutics
HealthQuad and British International Investment (BII) join earlier investors W Health Ventures, Kae Capital, pi Ventures and Google Assistant Investments.Read more>
Wysa has been named the "Best of" mental health apps in the Mozilla Foundation's latest *Privacy Not Included report on consumer privacy.Read more>
Wysa receives FDA Breakthrough Device Designation
The FDA has granted Breakthrough Device Designation for Wysa for adult patients suffering chronic musculoskeletal pain, depression and anxiety.
Users find Wysa helpful
Lead Author: Dr. Becky Inkster, University of Cambridge.
Every person and use case has unique needs, and Wysa is tailored to cater to each one.
Learn more about Wysa, the self-care library, and our professional support.
Premium access, co-branding, mental health campaigns, analytics and insights.
Co-branding, integrations, custom solutions for your healthcare needs and analytics.
Plug and play, scalable, premium access, co-branding, analytics and insights.
Wysa in the Spotlight
The app will help consumers keep a better track of their mental wellbeing and improve links to insurers’ existing support networks, which will enable a “win-win” through early intervention in the claims journey.
Disclaimer: Wysa is not designed to assist with crises such as abuse, severe mental health conditions that may cause feelings of suicide, harm to self, and any other medical emergencies. Wysa cannot and will not offer medical or clinical advice. It can only suggest that users seek advanced and professional medical help. Please reach out to your country-specific suicide hotline in case of an emergency.
Copyright 2022 at Wysa Ltd, All Rights Reserved.